Effect of Omacor on Triglycerides in HIV Infected Subjects
A Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Investigate the Effect of Omacor (n-3 PUFA) on Lipid Parameters in HIV Infected Subjects Treated With HAART
Sponsor: Solvay Pharmaceuticals
Terminated
The study was discontinued prematurely on December 18 2008 due to slow recruitment
Other terminated trials from Solvay Pharmaceuticals
- Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism · Phase NA · Oct 2018
- Prostate Cancer · Phase PHASE2 · Aug 2012
- Acute Decompensated Heart Failure; Renal Dysfunction · Phase PHASE2 · Jan 2010
- Obsessive Compulsive Disorder · Phase PHASE4 · Apr 2009
- Pancreatic Exocrine Insufficiency Due to Chronic Pancreatitis · Phase PHASE2 · Mar 2009
Listed as NCT00598910, this PHASE4 trial focuses on Hyper-Triglyceridemia and remains terminated or withdrawn. Sponsored by Solvay Pharmaceuticals, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Aug 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Solvay Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .